cyclopentane has been researched along with Adrenal Cortex Cancer in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Amendola, D; Avena, P; Campana, C; Carpinelli, G; Casaburi, I; Cerquetti, L; Chimento, A; De Luca, A; Domanico, F; Fallo, F; Malivindi, R; Martire, E; Pezzi, V; Rizza, P; Sirianni, R; Stigliano, A; Zolea, F | 1 |
1 other study(ies) available for cyclopentane and Adrenal Cortex Cancer
Article | Year |
---|---|
GPER agonist G-1 decreases adrenocortical carcinoma (ACC) cell growth in vitro and in vivo.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Animals; Apoptosis; Cell Cycle Checkpoints; Cell Proliferation; Cyclopentanes; DNA Damage; Female; Humans; Male; Mice; Mice, Nude; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Quinolines; Receptors, Estrogen; Receptors, G-Protein-Coupled; Signal Transduction | 2015 |